BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk...

DOACs associated with reduced risk of major bleeding compared to warfarin

DOACs associated with reduced risk of major bleeding compared to warfarin

July 11 2018 Direct oral anticoagulants (DOACs) have been associated with reduced risks of major...

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

Recorded penicillin allergy associated with increased risk of MRSA and C difficile

July 3 2018 People who have a record of penicillin allergy are at an increased risk of developing...

Syphilis and gonorrhoea diagnoses see significant increase

Syphilis and gonorrhoea diagnoses see significant increase

June 11 2018 Annual reporting of sexually transmitted infection diagnoses has increased 0.3% in...

Anticholinergics linked to increased risk of dementia

Anticholinergics linked to increased risk of dementia

April 30 2018 Anticholinergic drugs used in helping control some involuntary muscle movement...

  • BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    BMJ: ‘Adding a sulfonylurea to metformin looks safer than switching to one’

    Wednesday, 25 July 2018 13:55
  • DOACs associated with reduced risk of major bleeding compared to warfarin

    DOACs associated with reduced risk of major bleeding compared to warfarin

    Wednesday, 11 July 2018 13:11
  • Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Recorded penicillin allergy associated with increased risk of MRSA and C difficile

    Tuesday, 03 July 2018 16:42
  • Syphilis and gonorrhoea diagnoses see significant increase

    Syphilis and gonorrhoea diagnoses see significant increase

    Monday, 11 June 2018 14:16
  • Anticholinergics linked to increased risk of dementia

    Anticholinergics linked to increased risk of dementia

    Monday, 30 April 2018 12:08

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

malaria1November 3 2015

Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University's Jenner Institute, with partners Imaxio and GSK.

The Jenner Institute at Oxford University, together with partners Imaxio and GSK, has started a phase I clinical trial of a novel vaccine candidate aimed at blocking transmission of malaria.

Around half the world's population is at risk of malaria and the disease led to an estimated 584,000 deaths in 2013.  
MosquirixTM, a malaria vaccine candidate developed by GSK, has just received a positive scientific opinion from the European Medicines Agency for use in young children.  MosquirixTM aims at addressing the objectives set for a first generation vaccine in the WHO malaria vaccine technology roadmap. The roadmap also outlines ambitious goals for second generation vaccines including transmission-blocking vaccines. The latter prevent mosquitoes from transmitting malaria to non-infected persons.

The clinical trial is being conducted at Southampton, the lead trial site, and Oxford. It is a dose escalation study, where amounts of the potential vaccine are increased. The study will assess the safety of the vaccine candidate in people and its ability to generate immune responses that inhibit the growth of malaria eggs in mosquitos, preventing transmission of malaria.

The vaccine candidate, developed by the team led by Dr Sumi Biswas at the Jenner Institute, University of Oxford, is composed of a transmission-blocking antigen from Plasmodium falciparum, the more dangerous form of malaria. The antigen is combined with Imaxio's pro-immunogenic technology IMX313, designed to increase immune responses, and two viral vectors, which are virus carriers modified to be harmless but which can transport the vaccine elements into the body's cells. One of those is a proprietary viral vector from Okairos (acquired by GSK in 2014). It is being administered through a course of treatment developed by the Jenner Institute in Oxford.

"Blocking transmission of malaria by mosquitoes from human to human is increasingly seen as one several complementary ways to fight this very important disease." said Prof. Adrian Hill, Director of the Jenner Institute at Oxford University. "The malaria vaccine programme at the Jenner Institute is now unique in having vaccines against all stages of the parasite's life cycle in clinical development. The combination of technologies from Oxford, Imaxio & GSK is a very promising way to develop a transmission blocking vaccine candidate."

"After a first clinical trial involving our pro-immunogenic technology "IMX313" in 2013, we are very enthusiastic to see it reaching the clinic within a second vaccine candidate", said Mr. Alexandre Le Vert, Chief Executive Officer of Imaxio. "Collaborating with Oxford University's Jenner Institute and GSK in the development of vaccines is a great honour for us and reinforces our confidence in IMX313."

Funding

The trial is partly financed by the European Commission through MultiMalVax, a Collaborative Project funded by the EU's 7th Framework Programme (FP7) and coordinated by the Jenner Institute at the University of Oxford.

About the Jenner Institute at Oxford University

The Jenner Institute was founded in November 2005 to develop innovative vaccines against major global diseases. Uniquely it focuses both on diseases of humans and livestock and tests new vaccine approaches in parallel in different species. A major theme is translational research involving the rapid early-stage development and assessment of new vaccines in clinical trials.

malaria2

The Institute comprises the research activities of over 28 Jenner Investigators who head leading research groups spanning human and veterinary vaccine research and development. Together the Institute investigators comprise one of the largest non-profit sector research and development activities in vaccinology.

The Institute is a partnership between the University of Oxford and The Pirbright Institute. The Institute is supported by the Jenner Vaccine Foundation, a UK registered charity, and advised by the Jenner Institute Scientific Advisory Board.

mosquito3About Imaxio

Imaxio is a small biotechnology company focused on vaccines, with products ranging from commercial stage to clinical and preclinical R&D stages.

Its clinical-stage R&D pipeline is focused on vaccines for infectious diseases and immunotherapies in oncology. It includes five internal R&D projects plus seven active R&D collaborations, all based on a proprietary antigen re-engineering technology platform, called IMX313, which is designed to improve an antigen's immunogenicity. Using this technology, Imaxio works alongside several prominent international academic and industrial research teams to develop recombinant vaccines for infectious diseases (Influenza, Staphylococcus aureus, Tuberculosis, Malaria) and oncology.

Imaxio also commercializes in the French market a human vaccine indicated for the prevention of an infectious work-related disease, called Spirolept®.

The company owns a solid IP portfolio and collaborates with numerous international partners, including the Jenner Institute at Oxford University (UK). Twelve of the twenty Imaxio employees are dedicated to R&D activities. In 2014 its turnover reached EUR 2.3 million. Imaxio is based in Lyon, France.

Links:

Imaxio

Jenner Institute

Jenner Institute - Vaccines

Clinical News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...